ArticleBMC medicine2025
Association of biological aging acceleration transitions and burdens with incident cardiovascular disease: longitudinal insights from a national cohort study.
Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Cross-cohort insights into the association of handgrip strength transitions and burdens with cardiovascular disease risk.SSM - population health · 2026Article
- The role of epigenetic age acceleration and social disadvantage in cardiometabolic health in southeast Louisiana women.Clinical epigenetics · 2026Article
- Biological age acceleration, longitudinal change and mortality risk in the Dutch Lifelines cohort.GeroScience · 2026Article
- Associations of Biological Age and Heart Age Accelerations With New-Onset Stroke in Individuals With Cardiovascular-Kidney-Metabolic Syndrome Stages 0-3: Evidence From a Chinese Longitudinal Study.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
- Hematologic biomarkers of aging (HemeAge) and cardiovascular risk: a machine learning analysis in two cohorts.American journal of preventive cardiology · 2026Article
- Cross-cohort insights into the association of handgrip strength transitions and burdens with cardiovascular disease risk.medRxiv : the preprint server for health sciences · 2026Article
- Cardiac and systemic biological age capture complementary aging signals associated with cardiovascular disease.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPrevious studies have examined the association between biological aging acceleration (BioAgeAccel) and cardiovascular disease (CVD). However, the effects of BioAgeAccel transitions and burdens on CVD risk remained unclear, and little was known about the association of BioAgeAccel with age at CVD onset.
methodsWe included 316,417 participants from the UK Biobank in the baseline analyses and reserved 7249 in the visit-to-visit analyses. BioAgeAccel was defined as the residual derived from a linear regression of biological age against chronological age, with higher values indicating accelerated aging. We defined BioAgeAccel transitions based on aging status at baseline and the first follow-up, and created three indicators to reflect BioAgeAccel burdens. Cox models were used to evaluate the associations of baseline BioAgeAccel, BioAgeAccel transitions, and BioAgeAccel burdens with incident CVD risk. Linear models were employed to investigate their impacts on age at CVD onset.
resultsCompared to individuals maintaining stable non-accelerated aging patterns, those transitioning to accelerated aging status showed a 29.8% (4.2-61.8%) increased CVD risk, while participants with sustained accelerated aging demonstrated a more pronounced 65.5% (35.9-101.5%) risk elevation. Reversal from accelerated to non-accelerated aging status was associated with a significant 25.6% (3.9-42.3%) risk reduction compared to persistent accelerated aging. Higher BioAgeAccel burdens were related to enhanced incidence and advanced onset of CVD, all of which were greater than the effect of baseline BioAgeAccel, with cumulative BioAgeAccel showing the greatest influence on CVD risk (HR = 1.26 [1.07-1.47]) and the most pronounced contribution to earlier onset of CVD (0.989 [0.558-1.420] years). BioAgeAccel burdens were associated with a higher CVD risk compared to FRS or SCORE2 burdens and could enhance the predictive capacity of the two risk scores. Drug treatments did not substantially impact these results. We further discovered socioeconomic status likely antagonized the associations of BioAgeAccel burdens with CVD.
conclusionsThis study revealed BioAgeAccel progression was associated with a higher incident CVD risk, while its reversal was linked to a lower risk. BioAgeAccel burdens were associated with increased risk and earlier onset of CVD, exceeding the effects of baseline BioAgeAccel and some well-known risk scores, and cumulative BioAgeAccel exhibited the strongest impact among them.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.